Iran J Kidney Dis. 2025 Aug 15;19(3):165-171.
ABSTRACT
INTRODUCTION: The objective of this study was to evaluate the clinical efficacy of high-flux hemodialysis for treating uremia and its effect on microinflammation and nutritional status.
METHODS: This was a case-control study. One hundred and twenty patients under chronic hemodialysis in Qinhuangdao Haigang Hospital from June 2021 to June 2023 were randomly divided into experiment group and control groups, with 60 patients in each group. Patients in the experiment group received high-flux hemodialysis (HFHD), while those in the control group underwent conventional hemodialysis. The differences between the two groups regarding clinical efficacy, inflammatory factors including IL-6, CRP and TNF-a, and macromolecular toxins including β2-microglobulin, parathyroid hormone, and cysteine protease inhibitor were compared. The levels of nutritional indices including serum transferrin, albumin, and hemoglobin were compared between the two groups after 6 months of therapy. All patients were followed- up for 1.5 to 2 years, and the incidence of their cardiovascular and cerebrovascular events after treatment was analyzed.
RESULTS: The response rate (markedly effective + effective)/total number of cases × 100%.) was 93% in the experiment vs. 80% in the control group (P = .03). After treatment, IL-6, CRP, TNF-a, β2-microglobulin, parathyroid hormone, and cysteine protease inhibitor significantly reduced and serum transferrin, albumin and hemoglobin significantly improved in the experiment vs. control group (P = .00). At the end of the follow-up period the incidence of cardiovascular and cerebrovascular diseases was 7% in the experiment group, which was markedly lower than that of 22% in the control group (P = .02).
CONCLUSION: High-flux hemodialysis is a safe and effective treatment for uremia with remarkable clinical efficacy, offering various benefits such as significant reduction of inflammatory biomarkers and macromolecular toxins, improvement of patients' nutritional status, and reduction of the incidence of cardiovascular and cerebrovascular diseases.
PMID:42234878